ASX - By Stock
|
NEU |
Re:
Share Price
|
|
akpv
|
10K |
4.5M |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10K
|
4.5M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
akpv
|
544 |
239K |
7 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
544
|
239K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
akpv
|
315 |
156K |
2 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
315
|
156K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
akpv
|
315 |
156K |
3 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
315
|
156K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
akpv
|
10K |
4.5M |
0 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
10K
|
4.5M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Q3 2023 quarterly activity and cash flow report
|
|
akpv
|
16 |
7.9K |
3 |
20/10/23 |
20/10/23 |
ASX - By Stock
|
16
|
7.9K
|
3
|
|
ASX - By Stock
|
SP1 |
Re:
April-June ‘23 Quarterly Report
|
|
akpv
|
74 |
31K |
0 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
74
|
31K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Investor web conference presentation, 14 July 2023
|
|
akpv
|
35 |
14K |
26 |
16/07/23 |
16/07/23 |
ASX - By Stock
|
35
|
14K
|
26
|
|
ASX - By Stock
|
NEU |
Re:
Phelan-McDermid Syndrome
|
|
akpv
|
97 |
44K |
11 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
97
|
44K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Phelan-McDermid Syndrome
|
|
akpv
|
97 |
44K |
2 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
97
|
44K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Change of Director's Interest Notice
|
|
akpv
|
35 |
14K |
6 |
14/06/23 |
14/06/23 |
ASX - By Stock
|
35
|
14K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Neuren AGM 30th May
|
|
akpv
|
81 |
34K |
0 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
81
|
34K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
What will Neu with surplus funds ??
|
|
akpv
|
16 |
8.1K |
7 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
16
|
8.1K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Wilsons target $18.29 and summary
|
|
akpv
|
65 |
35K |
4 |
21/04/23 |
21/04/23 |
ASX - By Stock
|
65
|
35K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: FDA approves Daybue - the first treatment for Rett syndrome
|
|
akpv
|
74 |
29K |
8 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
74
|
29K
|
8
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: SP1 delisted from ASX
|
|
akpv
|
600 |
276K |
1 |
05/11/22 |
05/11/22 |
ASX - By Stock
|
600
|
276K
|
1
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: SP1 delisted from ASX
|
|
akpv
|
600 |
276K |
1 |
04/11/22 |
04/11/22 |
ASX - By Stock
|
600
|
276K
|
1
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: SP1 delisted from ASX
|
|
akpv
|
600 |
276K |
6 |
04/11/22 |
04/11/22 |
ASX - By Stock
|
600
|
276K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
akpv
|
10K |
4.5M |
4 |
04/11/22 |
04/11/22 |
ASX - By Stock
|
10K
|
4.5M
|
4
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: SP1 delisted from ASX
|
|
akpv
|
600 |
276K |
9 |
01/11/22 |
01/11/22 |
ASX - By Stock
|
600
|
276K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
akpv
|
10K |
4.5M |
3 |
19/10/22 |
19/10/22 |
ASX - By Stock
|
10K
|
4.5M
|
3
|
|
ASX - By Stock
|
MLD |
Re:
Ann: Thiess to move to compulsory acquisition
|
|
akpv
|
10 |
6.4K |
0 |
14/10/22 |
14/10/22 |
ASX - By Stock
|
10
|
6.4K
|
0
|
|
ASX - By Stock
|
MLD |
Re:
Ann: Thiess to move to compulsory acquisition
|
|
akpv
|
10 |
6.4K |
0 |
12/10/22 |
12/10/22 |
ASX - By Stock
|
10
|
6.4K
|
0
|
|
ASX - By Stock
|
MLD |
Re:
Ann: Thiess to move to compulsory acquisition
|
|
akpv
|
10 |
6.4K |
0 |
11/10/22 |
11/10/22 |
ASX - By Stock
|
10
|
6.4K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
akpv
|
955 |
479K |
22 |
13/08/22 |
13/08/22 |
ASX - By Stock
|
955
|
479K
|
22
|
|
ASX - By Stock
|
SP1 |
Re:
ISX vs ASX
|
|
akpv
|
1.8K |
754K |
14 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
1.8K
|
754K
|
14
|
|
ASX - By Stock
|
SP1 |
Re:
Flykk Money
|
|
akpv
|
870 |
267K |
6 |
20/04/22 |
20/04/22 |
ASX - By Stock
|
870
|
267K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
akpv
|
10K |
4.5M |
0 |
28/03/22 |
28/03/22 |
ASX - By Stock
|
10K
|
4.5M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
akpv
|
10K |
4.5M |
2 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
10K
|
4.5M
|
2
|
|
ASX - By Stock
|
NEU |
Re:
A De-risked bio-tech with 4X upside - Karst Peak Capital
|
|
akpv
|
73 |
44K |
9 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
73
|
44K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
A De-risked bio-tech with 4X upside - Karst Peak Capital
|
|
akpv
|
73 |
44K |
4 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
73
|
44K
|
4
|
|
ASX - By Stock
|
SP1 |
Re:
ISX Board Presentation
|
|
akpv
|
241 |
69K |
0 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
241
|
69K
|
0
|
|
ASX - By Stock
|
SP1 |
Re:
ASX "Spitballs" and Suspends iSignthis Ltd on Mere Suspicion
|
|
akpv
|
132 |
45K |
1 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
132
|
45K
|
1
|
|
ASX - By Stock
|
SP1 |
Re:
ASX "Spitballs" and Suspends iSignthis Ltd on Mere Suspicion
|
|
akpv
|
132 |
45K |
13 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
132
|
45K
|
13
|
|
ASX - By Stock
|
SP1 |
Re:
ISX vs ASX
|
|
akpv
|
1.8K |
754K |
0 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
1.8K
|
754K
|
0
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: Appendix 4D
|
|
akpv
|
5 |
2.6K |
5 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
5
|
2.6K
|
5
|
|
ASX - By Stock
|
SP1 |
Re:
ISX vs ASX
|
|
akpv
|
1.8K |
754K |
0 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
1.8K
|
754K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
TROFINETIDE TRIALS UPDATE
|
|
akpv
|
218 |
130K |
12 |
20/08/21 |
20/08/21 |
ASX - By Stock
|
218
|
130K
|
12
|
|
ASX - By Stock
|
SP1 |
Re:
ISX vs ASX
|
|
akpv
|
1.8K |
754K |
13 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
1.8K
|
754K
|
13
|
|
ASX - By Stock
|
SP1 |
Re:
ISX off-topic thread
|
|
akpv
|
3.5K |
9.5M |
3 |
22/07/21 |
22/07/21 |
ASX - By Stock
|
3.5K
|
9.5M
|
3
|
|
ASX - By Stock
|
SP1 |
Re:
Round 2 ISX vs ASX
|
|
akpv
|
1.9K |
658K |
2 |
15/03/21 |
15/03/21 |
ASX - By Stock
|
1.9K
|
658K
|
2
|
|
ASX - By Stock
|
SP1 |
Re:
Round 2 ISX vs ASX
|
|
akpv
|
1.9K |
658K |
1 |
15/03/21 |
15/03/21 |
ASX - By Stock
|
1.9K
|
658K
|
1
|
|
ASX - By Stock
|
SP1 |
Re:
Round 2 ISX vs ASX
|
|
akpv
|
1.9K |
658K |
0 |
19/11/20 |
19/11/20 |
ASX - By Stock
|
1.9K
|
658K
|
0
|
|
ASX - By Stock
|
SP1 |
Re:
Round 2 ISX vs ASX
|
|
akpv
|
1.9K |
658K |
1 |
17/11/20 |
17/11/20 |
ASX - By Stock
|
1.9K
|
658K
|
1
|
|
ASX - By Stock
|
SP1 |
Re:
Blockers from relisting on another exchange
|
|
akpv
|
11 |
2.7K |
13 |
27/10/20 |
27/10/20 |
ASX - By Stock
|
11
|
2.7K
|
13
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: Cont Disclosure Independent Expert Report & Supplementary
|
|
akpv
|
168 |
62K |
3 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
168
|
62K
|
3
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: Cont Disclosure Independent Expert Report & Supplementary
|
|
akpv
|
168 |
62K |
41 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
168
|
62K
|
41
|
|
ASX - By Stock
|
SP1 |
Re:
ASX Group Dealing Rules -19/82020
|
|
akpv
|
8 |
2.3K |
3 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
8
|
2.3K
|
3
|
|
ASX - By Stock
|
SP1 |
Re:
Visa’s Data Breach of ISX Customer Data
|
|
akpv
|
207 |
68K |
3 |
20/08/20 |
20/08/20 |
ASX - By Stock
|
207
|
68K
|
3
|
|
ASX - By Stock
|
SP1 |
Re:
Update on the Detail of the Independent Expert Report
|
|
akpv
|
34 |
9.9K |
1 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
34
|
9.9K
|
1
|
|